Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Mulet, Nuria
152  Ergebnisse:
Personensuche X
?
1

A randomised phase 2 study comparing different dose approac..:

Argilés, Guillem ; Mulet, Nuria ; Valladares-Ayerbes, Manuel...
European Journal of Cancer.  177 (2022)  - p. 154-163 , 2022
Link: https://doi.org/10.1016/..
 
?
2

BRAF, MEK and EGFR inhibition as treatment strategies in BR..:

Ros, Javier ; Baraibar, Iosune ; Sardo, Emilia...
Therapeutic Advances in Medical Oncology.  13 (2021)  - p. 175883592199297 , 2021
Link: https://doi.org/10.1177/..
 
?
3

Molecular subtypes and the evolution of treatment managemen..:

Martini, Giulia ; Dienstmann, Rodrigo ; Ros, Javier...
Therapeutic Advances in Medical Oncology.  12 (2020)  - p. 175883592093608 , 2020
Link: https://doi.org/10.1177/..
 
?
4

Impact of circulating tumor DNA mutant allele fraction on p..:

Elez, Elena ; Chianese, Chiara ; Sanz‐García, Enrique...
Molecular Oncology.  13 (2019)  9 - p. 1827-1835 , 2019
Link: https://doi.org/10.1002/..
 
?
5

Analysis of Fusobacterium persistence and antibiotic respon..:

Bullman, Susan ; Pedamallu, Chandra S. ; Sicinska, Ewa...
Science.  358 (2017)  6369 - p. 1443-1448 , 2017
Link: https://www.jstor.org/st..
 
?
6

Analysis ofFusobacteriumpersistence and antibiotic response..:

Bullman, Susan ; Pedamallu, Chandra S. ; Sicinska, Ewa...
Science.  358 (2017)  6369 - p. 1443-1448 , 2017
Link: https://doi.org/10.1126/..
 
?
7

Genomically matched therapy in refractory colorectal cancer..:

Mulet Margalef, Núria ; Castillo, Carmen ; Mosteiro, Miguel...
Molecular Oncology.  17 (2023)  9 - p. 1908-1916 , 2023
Link: https://doi.org/10.1002/..
 
?
8

A randomised phase 2 study comparing different dose approac..:

Argilés, Guillem ; Mulet, Nuria ; Valladares-Ayerbes, Manuel...
info:eu-repo/semantics/altIdentifier/pmid/36335783.  , 2022
Link: https://hdl.handle.net/1..
 
?
9

A randomised phase 2 study comparing different dose approac..:

Argilés, Guillem ; Mulet, Nuria ; Valladares-Ayerbes, Manuel...
http://hdl.handle.net/10668/22181.  , 2022
Link: http://hdl.handle.net/10..
 
?
10

A randomised phase 2 study comparing different dose approac..:

Argilés, Guillem ; Mulet, Nuria ; Valladares Ayerbes, Manuel...
Reproducció del document publicat a: https://doi.org/10.1016/j.ejca.2022.09.037.  , 2022
Link: http://hdl.handle.net/24..
 
?
11

BRAF, MEK and EGFR inhibition as treatment strategies in BR..:

Ros, Javier ; Baraibar, Iosune ; Sardo, Emilia...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903827/.  , 2021
Link: http://www.ncbi.nlm.nih...
 
?
12

Molecular subtypes and the evolution of treatment managemen..:

Martini, Giulia ; Dienstmann, Rodrigo ; Ros, Javier...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383645/.  , 2020
Link: http://www.ncbi.nlm.nih...
 
?
13

Impact of circulating tumor DNA mutant allele fraction on p..:

Elez, Elena ; Chianese, Chiara ; Sanz-García, Enrique...
Instituto de Salud Carlos III PI12-01589.  , 2019
Link: https://ddd.uab.cat/reco..
 
?
14

Changes In Serum CXCL13 Levels Are Associated With Outcomes..:

Cabrero-de las Heras, Sara ; Hernández-Yagüe, Xavier ; González, Andrea...
Biomedicine & Pharmacotherapy.  176 (2024)  - p. 116857 , 2024
Link: https://doi.org/10.1016/..
 
?
15

Challenges and Therapeutic Opportunities in the dMMR/MSI-H ..:

Mulet-Margalef, Núria ; Linares, Jenniffer ; Badia-Ramentol, Jordi...
Cancers.  15 (2023)  4 - p. 1022 , 2023
Link: https://doi.org/10.3390/..
 
1-15